Inhibiting NNMT Expression Lowering the expression of the NNMT enzyme isnt anything new under the sun, as it is well-connected to several disease states: NNMT is implicated in various disease conditions such as metabolic disorders, neurodegenerative diseases and cancer, and tissue NNMT expression or plasma levels of its product MNA have been proposed as biomarkers for these conditions Other chronic metabolic diseases that are linked to NNMT expression include: Insulin resistance & diabetes Heart disease Kidney disease Liver disease Parkinsons disease Chronic inflammation Im not suggesting that 5-Amino 1MQ will directly lead to reducing your risk of any of the diseases above that time will come when researchers finally smarten up and start testing the peptide in human clinical trials
10.1073/pnas.0501866102 Proc
Code Ocean , (2019)
To move Epitalon from experimental to evidence-based, several developments are essential: Randomized, double-blind, placebo-controlled clinical trials, ideally targeting specific endpoints (sleep, immune aging, telomere attrition) Toxicology and long-term safety studies, including exploration of stereoisomer effects and off-target consequences Validated delivery systems (e.g., dendrimer-conjugates, transdermal patches) that make real-world use feasible Pharmacodynamic biomarkers, to identify responders and track efficacy objectively over time Epitalon is not snake oil, but its also not a magic bullet
No less the exemption of the Covid vaccine manufactures from any liability for adverse effects
Whether you're researching peptide therapies for your practice or helping clients navigate emerging weight management options, understanding the science behind cagrilintide dosing protocols is crucial